Morgan Stanley

▲ Bull Case

• ◆WM compounding accelerates toward $10T client assets milestone, triggering investor-day re-rating. If MS hits $10T by H2 2026 and announces a $15T-by-FY2030 framework, WM-led multiple re-rates toward pure asset-manager comps (SCHW 17.87x, BLK ~17x). WM pre-tax income $12B at 19x multiple = $175B valuation = $111/share, pulling SOTP fair value to $200–235. Bull-case target: $215–235 (+9–19%).
• ◆IS cycle persists through FY27 with AI cost program delivering full $1.5B annualized savings by FY28. If M&A/IPO supercycle continues vs base-case normalization, FY27E EPS prints $14–15 (sell-side $12.42 plus upside) vs our base $12.50–13.00. AI cost win compresses efficiency ratio to 64–65% (from 67–68%), adding $1.5–2B annually. ROTCE sustains 23–24%; multiple defends 3.3–3.5x P/TBV.
• ◆Capital return plus share count reduction drive mechanical EPS/TBV/dividend growth. $18–22B/yr capital return = 6.3–7.0% yield; $95–105B over 5 years (~30% of market cap). Share count −3%/yr CAGR through FY30E (−14% cumulative). With 7–8% organic TBV growth, total return floor is 10–12%/yr from capital structure alone, and dividend has compounded 7–8%/yr since 2021 with 15+ year track record.

▼ Bear Case

• ◆IS cycle reverts in FY27 — historical base rate, not tail risk. IB cycles peak for 2–4 years; M&A backlog frozen 2022–2023 mostly executed. If FY27 IS revenue drops 25–30% from peak (normal outcome per base rates), FY27 EPS falls to $9–10. P/TBV compresses toward 10-yr median ~2.0x, stock targets $102–130 (−35 to −48%). Market currently prices 0% probability of this outcome.
• ◆Multiple de-rating from 3.44x P/TBV cyclical peak is asymmetric risk. MS at 3.44x P/TBV is the highest level since 2021 and ~50% above its 10-yr median. MS has rarely sustained above 2.4x P/TBV outside cyclical peaks. Even a normal re-rating to 2.5–2.7x — without earnings cuts — implies 20–25% downside. The MS-vs-GS pair-trade (MS +0.42x premium below historical 30–50%) does not rescue MS in absolute terms if both de-rate together.
• ◆WM margin durability unproven in market correction. The 30%+ WM pre-tax margin has only been tested in FY24–25 bull market. In a 20%+ equity correction, fee-based AUM compresses 15–20% while compensation costs (45% of revenue) are sticky → WM margin falls to 25–27%. In a 35%+ correction, WM margin drops below 22%, ROTCE to 8–10%, P/TBV to 0.6–0.8x → stock at $34–50 (−75 to −83%). This tail is ~5% probability but real.

“Primary debate: Is MS's WM-led model durably worth a premium to GS, or has the multiple already closed? MS trades at 3.44x P/TBV vs GS at 3.02x — a +0.42x premium (14% above GS). This is below the historical MS-GS P/TBV premium of 30–50%, which applied when GS was IB-heavy and MS was wealth-led. Bull side argues MS's superior recurring-revenue mix (55% vs GS 29%) and higher ROTCE (21.6% vs 16.5%) justify the premium and support expansion to 3.9–4.5x. Bear side notes both stocks are at 10-year P/TBV peaks and GS's AWM mix shift is closing the recurring-revenue gap, so the MS premium should compress, not expand. Our view: We are bearish on absolute multiples (both should de-rate over 12–24 months) but bullish on the relative trade — MS is the preferred long within Financials. The pair-trade (long MS / short GS at +0.42x premium, below historical 30–50%) carries positive expected value if the historical relationship reverts. The debate resolves over 4–6 quarters via Q2–Q3 2026 print sustainability, GS AWM execution, and MS investor-day framework announcement.”

• ◆Q2 2026 Earnings (July): EPS $3.00+ validates trajectory; pass +5–10%, fail (EPS <$2.50) −15–25%
• ◆$10T Client Assets Milestone + Investor Day $15T-by-FY2030 Framework (H2 2026–2027): Psychological + multiple re-rate; pass +5–15%, fail 0%
• ◆CCAR 2026 Stress Capital Buffer (June): Stable/reduced buffer ($4.0–4.3%); pass +3–5%, rise 50bps+ −8–12%
• ◆Basel III Endgame Final Rule (2026–2027): Lighter-than-draft outcome; pass +5–8%, harsher −10–15%
• ◆Asia WM Client Asset Disclosure (Quarterly): Asia WM >$300B with 15%+ growth validates franchise; pass +5–8%, stagnation −5–10%

• ◆Investment Banking Cycle Reversion in FY27 (HIGH severity, 30–35% probability): Historical base rate — IB cycles peak 2–4 years. If FY27 IS revenue drops 25–30% from Q1 26 record, EPS falls to $9–10, P/TBV compresses to ~2.0x, stock targets $102–130 (−35 to −48%). Mitigant: WM earnings floor; cost flexibility; prior cycle resilience.
• ◆Multiple De-rating from 3.44x P/TBV Cyclical Peak (HIGH severity, 50% base-rate probability): MS at 3.44x is the highest since 2021, ~50% above 10-yr median. Normal re-rating to 2.5–2.7x implies 20–25% downside even at flat earnings. Mitigant: None — multiple normalization is cyclical.
• ◆Wealth Management Margin Compression Below 27% (MEDIUM severity, 25–30% probability in correction): 30%+ WM pre-tax margin only tested in FY24–25 bull market. In a 20%+ equity correction, fee-based AUM compresses 15–20% while comp costs sticky → margin falls to 25–27%. In a 35%+ correction: WM margin <22%, ROTCE 8–10%, stock $34–50 (−75 to −83%). Mitigant: Fee-based shift provides partial protection; compensation lever exists.
• ◆Severe Market Dislocation Scenario (LOW probability ~5%, catastrophic severity): 2008-style stress; multiple structural compression + WM margin collapse + CET1 constraint. Stock targets $34–50 (−75 to −83%). Mitigant: Risk management; CCAR stress framework; capital buffer.